Bright minds biosciences inc DRUG.US Overview Analysis

US StockHealth Care
(No presentation for DRUG)

DRUG AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.

DRUG Current Performance

6.51%

Bright minds biosciences inc

1.31%

Avg of Sector

0.58%

S&P500

Top 10 High Relevance to DRUG

  • MGRX Mangoceuticals inc
    Value -Trend 2Swing Trading 2Whale Interest -Dividend 1
    See more

DRUG Profile

Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.

Price of DRUG